Interphone study reports on mobile phone use and brain cancer risk

The Interphone Study Group today published their results in the International Journal of Epidemiology. The paper presents the results of analyses of brain tumour (glioma and meningioma) risk in relation to mobile phone use in all Interphone study centres combined. This interview-based case-control study, which included 2708 glioma and 2409 meningioma cases and matched controls was conducted in 13 countries using a common protocol. Analyses of brain tumours in relation to mobile phone use have been reported from a number of cohort and case-control studies, including several of the national components of Interphone. No studies, however, have included as many exposed cases, particularly long-term and heavy users of mobile phones, as this study.

Background

Mobile phone use has increased dramatically since its introduction in the early-to-mid 1980’s. The expanding use of this technology has been accompanied by concerns about health. In the late 1990s, several expert groups critically reviewed the evidence on health effects of low-level exposure to radiofrequency (RF) electromagnetic fields, and recommended research into the possible adverse health effects of mobile telephone use.

IARC co-ordination of a multinational effort in cancer research

As a result, the International Agency for Research on Cancer (IARC) coordinated a feasibility study in 1998 and 1999, which concluded that an international study of the relationship between mobile phone use and brain tumour risk would be feasible and informative.

Scope of the Interphone study

Interphone was therefore initiated in 2000 as an international set of case-control studies in 13 countries around the world focusing on four types of tumours in tissues that most absorb RF energy emitted by mobile phones: tumours of the brain (glioma and meningioma), of the acoustic nerve (schwannoma), and of the parotid gland. The objective was to determine whether mobile phone use increases the risk of these tumours. Interphone is the largest case-control study of mobile phone use and brain tumours yet and includes the largest numbers of users with at least 10 years of exposure.

Scientific direction of Interphone

The Interphone International Study Group, made up of 21 scientists, was responsible for the progress of the study, the choice of analyses to be conducted, and the interpretation and publication of results. All the decisions about the study were made exclusively and collectively by the Interphone International Study Group. In the course of the study, the IARC Principal Investigator, Dr Elisabeth Cardis, moved to the Centre for Research in Environmental Epidemiology (CREAL) in Barcelona, Spain, where she continues her role as Interphone Principal Investigator, although the 13-country dataset remains at IARC.

Funding of Interphone

The Interphone study was undertaken as a collaborative effort between a number of partner institutions, co-ordinated by IARC. To date, the overall funding assigned to the Interphone study amounts to approx. 19.2 million euros (€). Of this amount 5.5 million € were contributed by industry sources.

Of these 5.5 million €, 3.5 million € were contributed by the Mobile Manufacturers’ Forum (MMF) and the GSM Association, each contributing half of that amount, through a firewall mechanism provided by the UICC (International...
Interphone study reports on mobile phone use and brain cancer risk

Union against Cancer) to guarantee the independence of the scientists. Most of the rest of the 5.5 million € came indirectly to individual centers from mobile phone operators and manufacturers, for example, through taxes and fees collected by government agencies. Only 0.5 million € (2.5%) of the overall study costs were provided directly by the industry, in Canada and France, under contracts which preserved the independence of the study.

Other funding was provided by the European Commission (3.74 million €) and national and local funding sources (9.9 million € in total) in participating countries.

Additional funding for the extension of the research to younger and older age groups was received directly from mobile phone operators in the UK under contracts which preserved the independence of the study.

Results

The Interphone Study Group summarized its findings as follows:

"A reduced odds ratio (OR)\textsuperscript{9} related to ever having been a regular mobile phone user was seen for glioma [OR 0.81; 95\% confidence interval (CI) 0.70-0.94] and meningioma (OR 0.79; 95\% CI 0.68-0.91), possibly reflecting participation bias or other methodological limitations. No elevated OR was observed ≥ 10 years after first phone use (glioma: OR 0.98; 95\% CI 0.76-1.26; meningioma: OR 0.83; 95\% CI 0.61-1.14). ORs were < 1.0 for all deciles of lifetime number of phone calls and nine deciles of cumulative call time. In the tenth [highest] decile of recalled cumulative call time, ≥1640 h, the OR was 1.40 (95\% CI 1.03-1.89) for glioma, and 1.15 (95\% CI 0.81-1.62) for meningioma; but there are implausible values of reported use in this group. ORs for glioma tended to be greater in the temporal lobe\textsuperscript{10} than in other lobes of the brain, but the CIs around the lobe-specific estimates were wide. ORs for glioma tended to be greater in subjects who reported usual phone use on the same side of the head as their tumour than on the opposite side."

Conclusions

The Interphone Study Group concluded with the following key message:

A reduced OR for glioma and meningioma related to ever having been a regular mobile phone user possibly reflects participation bias or other methodological limitations. No elevated OR for glioma or meningioma was observed ≥ 10 years after first phone use. There were suggestions of an increased risk of glioma, and much less so meningioma, in the highest decile of cumulative call time, in subjects who reported usual phone use on the same side of the head as their tumour and, for glioma, for tumours in the temporal lobe. Biases and errors limit the strength of the conclusions that can be drawn from these analyses and prevent a causal interpretation.

Change in pattern of use

The majority of subjects were not heavy mobile phone users by today's standards. The median lifetime cumulative call time was around 100 hours, with a median of 2 to 2½ hours of reported use per month. The cut-point for the heaviest 10\% of users (1640 hours lifetime), spread out over 10 years, corresponds to about a half-hour per day.

Today, mobile phone use has become much more prevalent and it is not unusual for young people to use mobile phones for an hour or more a day. This increasing use is tempered, however, by the lower emissions, on average, from newer technology phones, and the increasing use of texting and hands-free operations that keep the phone away from the head.

What next?

Dr Christopher Wild, Director of IARC said: "An increased risk of brain cancer is not established from the data from Interphone. However, observations at the highest level of cumulative call time and the changing patterns of mobile phone use since the period studied by Interphone, particularly in young people, mean that further investigation of mobile phone use and brain cancer risk is merited."

Professor Elisabeth Cardis said that "the Interphone study will continue with additional analyses of mobile phone use and tumours of the acoustic nerve and parotid gland." She added: "Because of concerns about the rapid increase in mobile phone use in young people – who were not covered by Interphone –, CREAL is co-ordinating a new project, MobiKidz, funded by the European Union, to investigate the risk of brain tumours from mobile phone use in childhood and adolescence."

IARC has scheduled a comprehensive review of the carcinogenic potential of mobile phone use under the auspices of its Monographs Programme. The review, scheduled for 24-31 May 2011, will consider all published epidemiological and experimental evidence, including the new data from the Interphone study.

\textsuperscript{9} The odds ratio (OR) is a measure of relative risk. In other terms, an OR of x is taken as meaning that people exposed have x times the risk of non-exposed people.

\textsuperscript{10} The temporal lobe is the region of the brain located nearest the ear.
Communication of results to media and interested parties

This press release was prepared jointly by IARC, UICC and CREAL. It was decided by the Interphone Study Group, and in conformity with the Study Protocol, that the IARC Communications Group, jointly with CREAL and UICC, would communicate with international partners, including the European Commission and the World Health Organization, a maximum of 7 days ahead of publication, under embargo conditions.

-ENDS-

Contacts for the media:

Pr Elisabeth Cardis, Interphone Principal Investigator: +34 932 147 312
Dr Christopher Wild, IARC Director: +33 472 738 567
Dr Vincent Cogliano, IARC Monographs: +33 472 738 476
Dr Nicolas Gaudin, IARC Communications: +33 472 738 567; +33 680 572 966
Dr Gisela Sanmartín Vidal, CREAL Communications: +34 932 147 333 / +34 696 912 841
ANNEX A: LIST OF MEMBERS AND CONTACT DETAILS

IARC/CREAL

- Professor Elisabeth Cardis
  Research Professor in Radiation Epidemiology
  CREAL-Centre for Research in Environmental Epidemiology
  Parc de Recerca Biomèdica de Barcelona (despatx 183)
  Doctor Aiguader, 88
  08003 Barcelona
  Spain
  Tel. +34 93 214 7312
  Fax +34 93 214 7302
  Email: ecardis@creal.cat
  Web: www.creal.cat

  Assistant: Eva Herrero
  Tel. + 34 93 2147340
  Fax  +34 93 2147302
  Email: eherrero@creal.cat

Australia

- Dr Bruce Armstrong
  Professor of Public Health
  Sydney School of Public Health
  The University of Sydney
  For appointments
  Sally Xexenis
  E-mail: sallyx@health.usyd.edu.au
  Tel. +61 2 9036 5040

  To contact Dr Bruce Armstrong directly
  Tel. +61 2 9036 6308
  Fax. +61 2 9036 7021
  E-mail: bruce.armstrong@sydney.edu.au
  Office: Room 324
  Edward Ford Building A27
  The University of Sydney - Camperdown Campus
  NSW 2006
  Map

- Dr Graham Giles
  Director, Cancer Epidemiology Centre
  The Cancer Council Victoria
  1 Rathdowne St, Carlton,
  Vic, 3053
  Email: graham.giles@cancervic.org.au

Canada

- Professor Daniel Krewski
  NSERC Chair in Risk Science
  Professor and Director
  McLaughlin Centre for Population Health Risk Assessment
  University of Ottawa
  Room 320, One Stewart Street
  Ottawa, Ontario K1N 6N5
  Tel. +1 (613) 562 5381
  Fax. +1 (613) 562 5380
  Web: www.mclaughlincentre.ca

  Administrative Assistant: Karin Bhookun, BA
  Tel. +1 (613) 562 5381
  Email: cphra@uottawa.ca
Interphone study reports on mobile phone use and brain cancer risk

- Professeur Marie-Élise Parent
  Institut national de la recherche scientifique
  Institut Armand-Frappier
  Unité d'épidémiologie et biostatistique
  531, boulevard des Prairies
  Laval (Québec) H7V 1B7
  Tel. +1 (450) 686 5676
  Fax. +1 (450) 686 5599
  Email: marie-elise.parent@iaf.inrs.ca
  Web: www.iaf.inrs.ca

- Professor Jack Siemiatycki
  Professor and Canada Research Chair in Environmental Epidemiology and Population Health
  Université de Montréal
  Research Center of CHUM
  3875 rue Saint-Urbain, 3rd floor
  Montréal Qc H2W 1v1
  Tel. +1 (514) 890 8166
  Fax. +1 (514) 412 7106
  Email: j.siemiatycki@umontreal.ca

- Dr Mary McBride
  Cancer Control Research Program
  B.C. Cancer Agency
  600 W. 10th Avenue
  Vancouver, BC V5Z 4E6
  Tel. +1 (604) 675 8059
  Fax. +1 (604) 877 1868
  Email: mmcbride2@bccancer.bc.ca

Denmark
- Dr Christoffer Johansen
  Head, Department of Psychosocial Cancer Research
  Institute of Cancer Epidemiology
  Copenhagen
  Tel. +45 35 25 76 27
  Email: christof@cancer.dk

Finland
- Dr Anssi Auvinen
  Department of Epidemiology
  University of Tampere
  Tampere School of Public Health
  Medisiinarinkatu 3,
  33520 Tampere
  Tel. +358 335 516 883
  Fax +358 335 516 057
  Email: auvinen@uta.fi

France
- Dr Martine Hours
  Médecin Epidémiologiste
  Unité Mixte de Recherche épidémiologique et de surveillance
  Transport Travail Environnement
  8, avenue Rockefeller
  69373 Lyon Cedex 08
  Tel. +33 472 142 522
  Fax. +33 478 742 582
  Email: martine.hours@inrets.fr
Interphone study reports on mobile phone use and brain cancer risk

Germany

- Dr. Joachim Schüz
  Head, Department of Biostatistics and Epidemiology
  Institute of Cancer Epidemiology
  Danish Cancer Society
  Strandboulevarden 49
  DK-2100 Copenhagen
  Tel. +45 35 25 76 55
  Fax. +45 35 25 77 31
  Email: joachim@cancer.dk

- Professor Maria Blettner
  Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI)
  Universitätsmedizin der Johannes Gutenberg - Universität Mainz
  Obere Zahlbacher Strasse 69
  55131 Mainz
  Tel. +49 61 31 17 32 52
  Fax. +49 61 31 17 29 68
  E-mail: blettner@imbei.uni-mainz.de

Israel

- Professor Siegal Sadetzki
  Head, Cancer and Radiation Epidemiology Unit
  The Gertner Institute for Epidemiology and Health Policy Research
  The Chaim Sheba Medical Centre
  52 621 Tel-Aviv
  The Sackler School of Medicine, Tel Aviv University
  69 978 Tel-Aviv
  Tel. +972 (3) 530 3262
  Fax. +972 (3) 534 8360
  Email: siegals@gertner.health.gov.il

Italy

- Dr. Susanna Lagorio
  Senior Researcher
  National Centre for Epidemiology Surveillance and Health Promotion (CNESPS)
  Istituto Superiore di Sanità
  Viale Regina Elena, 299
  00161 Rome
  Tel. +39 649 904 304
  Fax. +39 649 904 305
  Email: susanna.lagorio@iss.it

Japan

- Professor Naohito Yamaguchi
  Chairperson
  Department of Hygiene and Public Health
  Tokyo Women's Medical University
  8-1 Kawadacho, Shinjuku-ku
  Tokyo 162-8666
  Tel. +81 333 538 111 ext 22121
  Fax. +81 352 697 420
  Email: nyamaguc@vega.ocn.ne.jp

- Professor Toru Takebayashi
  Department of Preventive Medicine and Public Health
  Keio University School of Medicine
  35 Shinanomachi, Shinjuku-ku
  Tokyo 160-8582
  Tel. +81 353 633 756
  Fax. +81 333 580 439
  Email: ttake@sc.itc.keio.ac.jp
Interphone study reports on mobile phone use and brain cancer risk

New Zealand
- **Professor Alistair Woodward**
  School of Population Health
  University of Auckland
  Private Bag 92019
  Auckland 1142
  Tel. +64 93 73 75 99 (ext 86361)
  Email: a.woodward@auckland.ac.nz

Norway
- **Dr Tore Tynes**
  Department of Occupational Health Surveillance, NOA
  National Institute of Occupational Health
  PO Box 8149 Dep
  0033 Oslo
  Tel. +47 23 19 51 61
  Fax. +47 23 19 52 00
  Email: tore.tynes@stami.no

Sweden
- **Dr Maria Feychting**
  Professor of Epidemiology
  Institute of Environmental Medicine
  Karolinska Institute
  Box 210
  S-171 77 Stockholm
  Tel. +46 852 487 465
  Fax. +46 8313961
  Email: maria.feychting@ki.se

United Kingdom
- **Professor Anthony Swerdlow**
  Sir Richard Doll Building
  Institute of Cancer Research,
  Cotswold Road, Sutton,
  Surrey SM2 5NG
  Tel. +44 208 722 4012
  E-mail: anthony.swerdlow@icr.ac.uk

- **Professor Patricia McKinney**
  Division of Epidemiology
  Leeds Institute of Genetics, Health and Therapeutics
  Room 8.49j, Level 8, Worsley Building
  University of Leeds
  Leeds
  LS2 9JT
  Email: p.a.mckinney@leeds.ac.uk
### ANNEX B: LIST OF PARTICIPATING INSTITUTIONS

**Australia**  
- Cancer Council New South Wales  
- Cancer Council Victoria  
- The University of Sydney  

**Canada**  
- University of Ottawa, Faculty of Medicine, Epidemiology and Community Medicine  
- INRS-Institut Armand Frappier, Université du Québec, Laval, Québec  
- CRCHUM, Université de Montréal, Montréal, Québec  
- Cancer Control Research, British Columbia Cancer Agency, Vancouver  

**Denmark**  
- Division for Cancer Epidemiology, Danish Cancer Society, Copenhagen  

**Finland**  
- Finnish Centre for Radiation and Nuclear Safety, Helsinki  

**France**  
- Institut de Médecine du Travail, Lyon  

**Germany**  
- Institute of Medical Biostatistics, Epidemiology and Informatics, University of Mainz, Mainz (coordination)  
- Department of Epidemiology and International Public Health, University of Bielefeld, Bielefeld  
- Unit of Environmental Epidemiology, German Cancer Research Center, Heidelberg  

**Israel**  
- Chaim Sheba Medical Center, Tel-Hashomer  

**Italy**  
- Istituto Superiore di Sanità, Rome  

**Japan**  
- Tokyo Women's Medical University, Tokyo, Japan  

**New Zealand**  
- Wellington School of Medicine, University of Otago, Wellington South  
- School of Population Health, University of Auckland  
- Centre for Public Health Research, Massey University  

**Norway**  
- Norwegian Radiation Protection Authority, Osterås  

**Sweden**  
- Karolinska Institute, Institute of Environmental Medicine, Division of Epidemiology, Stockholm  

**United Kingdom**  
- Faculty of Medicine and Health, University of Leeds, Leeds  
- National Radiological Protection Board, Didcot  
- Scottish Cancer Intelligence Unit, NHS, Scotland  
- Section of Epidemiology, Institute of Cancer Research, Sutton  

**International Organizations**  
- International Agency for Research on Cancer (IARC), Lyon, France